View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 10, 2019updated 23 Dec 2019 12:05pm

Anavex initiates ANAVEX 2-73 study in Alzheimer disease

Clinical-stage biopharmaceutical company Anavex Life Sciences has initiated a long-term extension study for patients with early Alzheimer’s disease (AD) and treated with ANAVEX2-73 (blarcamesine).

Clinical-stage biopharmaceutical company Anavex Life Sciences has initiated a long-term extension study for patients with early Alzheimer’s disease (AD) and treated with ANAVEX2-73 (blarcamesine).

Blarcamesine is an orally available, small-molecule activator of the sigma-1 receptor. It is indicated a play a key role in restoring neural cell homeostasis and promoting neuroplasticity.

The open label study, ATTENTION-AD, is an extension of the ongoing Phase IIb/III ANAVEX2-73-AD-004 clinical study. Phase IIb/III is a placebo-controlled trial conducted over 48 weeks.

Principal investigator for both studies Stephen Macfarlane said: “This is an important development as the patients who have completed the main study, ANAVEX2-73-AD-004, are consistently expressing the wish to gain ongoing access to this investigational therapy.”

ATTENTION-AD will be carried out for two years and will involve AD patients who participated in the ANAVEX2-73-AD-004 study.

Patients can enrol in the extension study only after completing the placebo-controlled Phase IIb/III trial.

ATTENTION-AD will provide additional tolerability and efficacy data and will be performed together with the Phase IIb/III ANAVEX2-73-AD-004 study.

Anavex chief executive officer Christopher U Missling said: “People living with Alzheimer’s disease desperately need new therapies and ATTENTION-AD reflects our commitment to the patients who participated in the Phase IIb/III ANAVEX 2-73-AD-004 study and who have contributed enormously to the development of a potential new medicine for patients with early Alzheimer’s disease.

“This study will provide supplemental data on ANAVEX 2-73 (blarcamesine).”

The company’s ANAVEX 2-73 has already completed a successful Phase IIa clinical trial for AD.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena